StockNews.AI

Published Peer-Reviewed Study Demonstrates Nexalin's DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD

StockNews.AI • 1 minute

ADHDN/A
High Materiality9/10

Information

HOUSTON, TX, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company”...

Original source

AI Summary

Nexalin Technology's recent publication of a clinical study demonstrated their DIFS™ technology significantly reduces ADHD symptoms through neurostimulation. With substantial improvements in both clinical outcomes and brain activity metrics, this positions Nexalin well in the neurostimulation market, signaling potential investor interest and share price growth.

Sentiment Rationale

Positive validation of DIFS™ aligns with market demand for non-invasive mental health treatments. Previous studies have shown strong price reactions to successful trial results in pharmaceutical companies.

Trading Thesis

Invest in Nexalin (NXL) for potential growth driven by successful clinical validation of DIFS™.

Market-Moving

  • Positive clinical study results could lead to increased demand for Nexalin's products.
  • FDA approval expectations may be heightened post-study results.
  • Market reaction expected as ADHD treatment validation trends arise.
  • Possible partnerships with pharmaceutical companies based on positive outcomes.

Key Facts

  • Nexalin published positive study results for DIFS™ in ADHD treatment.
  • Study showed significant reduction in ADHD symptoms with active neurostimulation.
  • Participants improved by 10.1 points on ADHD scale versus 5.5 points in sham group.
  • DIFS™ technology reduces excessive gamma brain activity related to ADHD.
  • Positive results supported by objective neuroimaging data from EEG and MEG.

Companies Mentioned

  • Peking University Sixth Hospital (N/A): Conducted the significant clinical study validating Nexalin's technology.

Corporate Developments

This news fits under 'Corporate Developments' as it highlights key advancements in Nexalin's product validation, demonstrating a solid step in their strategic growth in the mental health sector.

Nexalin Technology, Inc. Announces Groundbreaking Study on DIFS™ Neurostimulation for ADHD

HOUSTON, TX, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL), a leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology, has published a new peer-reviewed clinical study in Molecular Psychiatry. This landmark research demonstrates that Nexalin’s DIFS™ technology produces significant and positive changes in brain activity among participants suffering from Attention Deficit Hyperactive Disorder (ADHD).

Clinical Study Overview

The randomized, double-blind, sham-controlled trial involved 56 adult participants diagnosed with ADHD, who underwent four weeks of Nexalin's frequency-based neurostimulation. The study tracked brain activity using advanced imaging techniques such as electroencephalography (EEG) and magnetoencephalography (MEG).

Findings revealed that participants receiving active treatment experienced a 10.1-point average improvement on the Adult ADHD Self-Report Scale, compared to a 5.5-point improvement in the sham group. This substantial metric indicates a statistically significant difference (p < 0.001) between the two groups.

Technical Insights and Implications

Importantly, the scope of this study extended beyond conventional symptom checklists. The integration of MEG allowed researchers to observe a reduction in excessive gamma-frequency brain activity—an abnormality often linked to ADHD, characterized by racing thoughts and distractibility.

  • Reduced gamma activity indicates improved cognitive function.
  • Normalization of communication between key brain networks involved in attention and focus.
  • Participants demonstrated reductions in symptoms associated with ADHD, anxiety, and depression.

Safety and Efficacy

Throughout the study, participants reported significant improvements in concentration, mood, and sleep quality. Importantly, the treatment exhibited a safety profile comparable to sham stimulation, with no serious adverse events reported.

Mark White, CEO of Nexalin Technology, emphasized the significance of the study, stating, “This study represents an important milestone for Nexalin and for the field of non-invasive neurostimulation. The clinical improvements were supported by objective brain imaging data, showcasing measurable normalization of abnormal brain activity.”

Scientific and Clinical Significance

According to Dr. David Owens, Chief Medical Officer of Nexalin, the study is pivotal as it transitions from mere symptom evaluations towards examining fundamental brain functions. The results provide promising evidence that Nexalin’s DIFS™ technology, a non-invasive approach, can regulate abnormal neural signaling contributing to attention deficits.

This research reflects a broader shift in understanding mental health conditions, recognizing them as disorders of brain network regulation rather than isolated chemical imbalances. ADHD currently affects millions globally, and Nexalin aims to offer a drug-free therapeutic avenue that addresses the underlying neural dysregulation.

About Nexalin Technology, Inc.

Nexalin Technology, Inc. designs innovative neurostimulation products targeted at the global mental health crisis. The company's DIFS™ technology is non-invasive, drug-free, and is engineered to modulate disrupted brain networks associated with mental health disorders. Nexalin's devices have received regulatory approval in multiple international markets.

For more information, visit Nexalin's official website.

Related News